Topical treatment of vaginal dryness with a non-hormonal cream in women undergoing breast cancer treatment - An open prospective
![Biomedicines | Free Full-Text | Anti-HER2/neu Antibody Reduces Chemotherapy-Induced Ovarian Toxicity—From Bench to Bedside Biomedicines | Free Full-Text | Anti-HER2/neu Antibody Reduces Chemotherapy-Induced Ovarian Toxicity—From Bench to Bedside](https://www.mdpi.com/biomedicines/biomedicines-08-00577/article_deploy/html/images/biomedicines-08-00577-g004.png)
Biomedicines | Free Full-Text | Anti-HER2/neu Antibody Reduces Chemotherapy-Induced Ovarian Toxicity—From Bench to Bedside
![Congreso Apanac on Twitter: "Uno de los conferencistas invitados al Congreso es el Dr. Salomon Stemmer, Jefe de Investigación e Innovación en el Instituto de Oncología del Centro Davidoff del Centro Médico Congreso Apanac on Twitter: "Uno de los conferencistas invitados al Congreso es el Dr. Salomon Stemmer, Jefe de Investigación e Innovación en el Instituto de Oncología del Centro Davidoff del Centro Médico](https://pbs.twimg.com/media/Ez7dLf1XoAA82Ad.jpg)
Congreso Apanac on Twitter: "Uno de los conferencistas invitados al Congreso es el Dr. Salomon Stemmer, Jefe de Investigación e Innovación en el Instituto de Oncología del Centro Davidoff del Centro Médico
![Development and Validation of a Tool Integrating the 21-Gene Recurrence Score and Clinical-Pathological Features to Individualize Prognosis and Prediction of Chemotherapy Benefit in Early Breast Cancer | Journal of Clinical Oncology Development and Validation of a Tool Integrating the 21-Gene Recurrence Score and Clinical-Pathological Features to Individualize Prognosis and Prediction of Chemotherapy Benefit in Early Breast Cancer | Journal of Clinical Oncology](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/jco/2021/jco.2021.39.issue-6/jco.20.03007/20210209/images/large/jco.20.03007t1.jpeg)